Using 68Ga-TCR-FAPI PETCT Imaging to Guide Surgery for Medullary Thyroid Cancer in Adults Aged 18 to 75

What this Trial Is About

This research aims to evaluate the use of a specialized imaging technique called 68Ga-labeled targeted covalent radiopharmaceutical TCR fibroblast activation protein inhibitor FAPI PETCT to guide surgery for medullary thyroid carcinoma MTC. Surgery is currently the only curative option for MTC, but existing imaging methods and calcitonin tests are not sufficient to fully map the disease. This study focuses on whether 68Ga-TCR-FAPI PETCT can better identify the extent of MTC and improve surgical planning. Participants are divided into three groups those newly diagnosed with MTC, those with recurrent or persistent MTC after prior treatment, and those with distant or unresectable lesions but still recommended for surgery. Surgery will be performed based on the lesion range revealed by the 68Ga-TCR-FAPI PETCT scan, aiming to remove all identified lesions when possible. The surgical principles follow current standards, including lymph node dissection when needed. During the study, researchers will measure calcitonin levels one month after surgery as the primary outcome. Secondary outcomes include two-year event-free survival, how often surgical plans change based on imaging results, and the accuracy of 68Ga-TCR-FAPI PETCT in detecting MTC lesions. Participants will undergo PETCT scans, surgery guided by imaging findings, and follow-up assessments to monitor outcomes and safety up to two years after surgery.

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC